刘耀琨,郑博,霍勇

• 1:北京大学第一医院心内科心血管疾病研究所

摘要(Abstract)：

本文盘点总结2023年度冠心病领域重要临床研究进展。通过Web of Science网站，以“heart”“cardi~*”“myocardi~*”“coronary”“arrhythmi~*”“valv~*”“hypertension”等作为关键词，从顶级医学期刊中进行检索，最终筛选出引用较高且笔者认为对临床诊疗更具现实指导价值的论著，主要聚焦于腔内影像、血运重建策略、支架内再狭窄、抗血小板治疗以及血脂调控等方面。从提高和优化诊疗技术到新药研发，切实减轻全球冠心病负担。

关键词(KeyWords)： 腔内影像;血运重建策略;支架内再狭窄;抗血小板治疗;血脂调控

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘耀琨,郑博,霍勇

参考文献(References)：

• [1]Hong SJ,Mintz GS,Ahn CM,et al.Effect of intravascular ultrasound-guided drug-eluting stent implantation:5-year followup of the IVUS-XPL randomized trial[J].JACC Cardiovasc Interv,2020,13(1):62-71.DOI:10.1016/j.jcin.2019.09.033.
• [2]Gao XF,Ge Z,Kong XQ,et al.3-year outcomes of the ULTIMATE trial comparing intravascular ultrasound versus angiography-guided drug-eluting stent implantation[J].JACC Cardiovasc Interv,2021,14(3):247-257.DOI:10.1016/j.jcin.2020.10.001.
• [3]Chieffo A,Latib A,Caussin C,et al.A prospective,randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions:the AVIO trial[J].Am Heart J,2013,165(1):65-72.DOI:10.1016/j.ahj.2012.09.017.
• [4]Ali ZA,Maehara A,Genereux P,et al.Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation(ILUMIENⅢ:OPTIMIZE PCI):a randomised controlled trial[J].Lancet,2016,388(10060):2618-2628.DOI:10.1016/S0140-6736(16)31922-5.
• [5]Lee JM,Choi KH,Song YB,et al.Intravascular imaging-guided or angiography-guided complex PCI[J].N Engl J Med,2023,388(18):1668-1679.DOI:10.1056/NEJMoa2216607.
• [6]Holm NR,Andreasen LN,Neghabat O,et al.OCT or angiography guidance for PCI in complex bifurcation lesions[J].N Engl J Med,2023,389(16):1477-1487.DOI:10.1056/NEJMoa2307770.
• [7]Ali ZA,Landmesser U,Maehara A,et al.Optical coherence tomography-guided versus angiography-guided PCI[J].N Engl JMed,2023,389(16):1466-1476.DOI:10.1056/NEJMoa2305861.
• [8]He L,Zhang D,Xu Y,et al.Benefits of an OCT-based reperfusion strategy in STEMI:1-year angiographic follow-up of EROSIONⅢ[J].JACC Cardiovasc Imaging,2023,16(3):390-392.DOI:10.1016/j.jcmg.2022.10.006.
• [9]Kuno T,Kiyohara Y,Maehara A,et al.Comparison of intravascular imaging,functional,or angiographically guided coronary intervention[J].J Am Coll Cardiol,2023,82(23):2167-2176.DOI:10.1016/j.jacc.2023.09.823.
• [10]Lawton JS,Tamis-Holland JE,Bangalore S,et al.2021 ACC/AHA/SCAI guideline for coronary artery revascularization:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].Circulation,2022,145(3):e4-e17.DOI:10.1161/CIR.0000000000001038.
• [11]Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS guidelines on myocardial revascularization[J].Eur Heart J,2019,40(2):87-165.DOI:10.1093/eurheartj/ehy394.
• [12]Byrne RA,Rossello X,Coughlan JJ,et al.2023 ESC guidelines for the management of acute coronary syndromes[J].Eur Heart J,2023,44(38):3720-3826.DOI:10.1093/eurheartj/ehad191.
• [13]Kang DY,Ahn JM.Yun SC,et al.Optical coherence tomographyguided or intravascular ultrasound-guided percutaneous coronary intervention:the OCTIVUS randomized clinical trial[J].Circulation,2023,148(16):1195-1206.DOI:10.1161/CIRCULATIONAHA.123.066429.
• [14]Li YX,Wang BN,Fan FF,et al.Thirty-day outcomes of inhospital multi-vessel versus culprit-only revascularization strategy for ST-segment elevation myocardial infarction with multivessel coronary disease[J].J Geriatr Cardiol,2023,20(7):485-494.DOI:10.26599/1671-5411.2023.07.005.
• [15]Mehta SR,Wood DA,Storey RF,et al.Complete revascularization with multivessel PCI for myocardial infarction[J].N Engl J Med,2019,381(15):1411-1421.DOI:10.1056/NEJMoa1907775.
• [16]Lee JM,Kim HK,Park KH,et al.Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease:a randomized trial[J].Eur Heart J,2023,44(6):473-484.DOI:10.1093/eurheartj/ehac763.
• [17]Biscaglia S,Guiducci V,Escaned J,et al.Complete or culprit-only PCI in older patients with myocardial infarction[J].N Engl J Med,2023,389(10):889-898.DOI:10.1056/NEJMoa2300468.
• [18]Diletti R,den Dekker WK,Bennett J,et al.Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease(BIOVASC):a prospective,open-label,non-inferiority,randomised trial[J].Lancet,2023,401(10383):1172-1182.DOI:10.1016/S0140-6736(23)00351-3.
• [19]Iqbal MB,Nadra IJ,Ding L,et al.Culprit vessel versus multivessel versus in-hospital staged intervention for patients with ST-segment elevation myocardial infarction and multivessel disease:stratified analyses in high-risk patient groups and anatomic subsets of nonculprit disease[J].JACC Cardiovasc Interv,2017,10(1):11-23.DOI:10.1016/j.jcin.2016.10.024.
• [20]Manari A,Varani E,Guastaroba P,et al.Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only,immediate,or staged multivessel percutaneous revascularization strategies:insights from the REAL registry[J].Catheter Cardiovasc Interv,2014,84(6):912-922.DOI:10.1002/ccd.25374.
• [21]Fukutomi M,Toriumi S,Ogoyama Y,et al.Outcome of staged percutaneous coronary intervention within two weeks from admission in patients with ST-segment elevation myocardialinfarction with multivessel disease[J].Catheter Cardiovasc Interv,2019,93(5):E262-e268.DOI:10.1002/ccd.27896.
• [22]Rajkumar CA,Foley MJ,Ahmed-Jushuf F,et al.A Placebocontrolled trial of percutaneous coronary intervention for stable angina[J].N Engl J Med,2023,389(25):2319-2330.DOI:10.1056/NEJMoa2310610.
• [23]Boden WE,O'Rourke RA,Teo KK,et al.Optimal medical therapy with or without PCI for stable coronary disease[J].N Engl J Med,2007,356(15):1503-1516.DOI:10.1056/NEJMoa070829.
• [24]Spertus J,Mark D.ISCHEMIA trial update[J].Am Heart J,2019,218:8.DOI:10.1016/j.ahj.2019.09.001.
• [25]Al-Lamee R,Thompson D,Dehbi HM,et al.Percutaneous coronary intervention in stable angina(ORBITA):a double-blind,randomised controlled trial[J].Lancet,2018,391(10115):31-40.DOI:10.1016/S0140-6736(17)32714-9.
• [26]Rittger H,Waliszewski M,Brachmann J,et al.Long-term outcomes after treatment with a paclitaxel-coated balloon versus balloon angioplasty:insights from the PEPCAD-DES study(Treatment of Drug-eluting Stent[DES]In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty[PTCA]Catheter)[J].JACC Cardiovasc Interv,2015,8(13):1695-1700.DOI:10.1016/j.jcin.2015.07.023.
• [27]Wong YTA,Kang DY,Lee JB,et al.Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis:a randomized RESTORE trial[J].Am Heart J,2018,197:35-42.DOI:10.1016/j.ahj.2017.11.008.
• [28]Giacoppo D,Alfonso F,Xu B,et al.Paclitaxel-coated balloon angioplasty vs.drug-eluting stenting for the treatment of coronary instent restenosis:a comprehensive,collaborative,individual patient data meta-analysis of 10 randomized clinical trials(DAEDALUS study)[J].Eur Heart J,2020,41(38):3715-3728.DOI:10.1093/eurheartj/ehz594.
• [29]Giacoppo D,Alvarez-Covarrubias HA,Koch T,et al.Coronary artery restenosis treatment with plain balloon,drug-coated balloon,or drug-eluting stent:10-year outcomes of the ISAR-DESIRE 3 trial[J].Eur Heart J,2023,44(15):1343-1357.DOI:10.1093/eurheartj/ehad026.
• [30]Koch T,Lenz T,Rheude T,et al.Recurrent revascularization at 10years after percutaneous treatment of drug-eluting stent restenosis[J].JACC Cardiovasc Interv,2024,17(1):1-13.DOI:10.1016/j.jcin.2023.10.031.
• [31]De Caterina R,Giannessi D,Bernini W,et al.A prostacyclinsparing effect of indobufen vs.aspirin[J].Thromb Haemost,1996,75(3):510-514.
• [32]Lee JY,Sung KC,Choi HI.Comparison of aspirin and indobufen in healthy volunteers[J].Platelets,2016,27(2):105-109.DOI:10.3109/09537104.2015.1042853.
• [33]Wu H,Xu L,Zhao X,et al.Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation(OPTION):a randomized,open-label,end point-blinded,noninferiority trial[J].Circulation,2023,147(3):212-222.DOI:10.1161/CIRCULATIONAHA.122.0627262.
• [34]Ohman EM,Roe MT,Steg PG,et al.Clinically significant bleeding with low-dose rivaroxaban versus aspirin,in addition to P2Y,2inhibition,in acute coronary syndromes(GEMINI-ACS-1):a double-blind,multicentre,randomised trial[J].Lancet,2017,389(10081):1799-1808.DOI:10.1016/S0140-6736(17)30751-1.
• [35]Latib A,Ielasi A,Ferri L,et al.Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation:a proposed alternative regimen[J].Int J Cardiol,2013,165(3):444-447.DOI:10.1016/j.ijcard.2011.08.080.
• [36]Mendieta G,Pocock S,Mass V,et al.Determinants of progression and regression of subclinical atherosclerosis over 6 years[J].J Am Coll Cardiol,2023,82(22):2069-2083.DOI:10.1016/j.jacc.2023.09.814.
• [37]Nissen SE,Lincoff AM,Brennan D,et al.Bempedoic acid and cardiovascular outcomes in statin-intolerant patients[J].N Engl J Med,2023,388(15):1353-1364.DOI:10.1056/NEJMoa2215024.
• [38]Pinkosky SL,Newton RS,Day EA,et al.Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis[J].Nat Commun,2016,7:13457.DOI:10.1038/ncomms13457.
• [39]Ray KK,Wright RS,Kallend D,et al.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J].N Engl J Med,2020,382(16):1507-1519.DOI:10.1056/NEJMoa1912387.
• [40 Raal FJ,Kallend D,Ray KK,et al.Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J].N Engl J Med,2020,382(16):1520-1530.DOI:10.1056/NEJMoa1913805.
• [41]Wright RS,Ray KK,Raal FJ,et al.Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J].J Am Coll Cardiol,2021,77(9):1182-1193.DOI:10.1016/j.jacc.2020.12.058.
• [42]Wright RS.ORION-8:Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients[EB/OL].(2023-08-23)[2023-12-18].https://esc365.escardio.org/presentation/272197.
• [43]Huo Y,Lesogor A,Lee CW,et al.Efficacy and safety of inclisiran in Asian patients:results from ORION-18[J/OL].JACC:Asia.(2023-11-14)[2023-12-18].https://doi.org/10.1016/j.jacasi.2023.09.006.
• [44]Ballantyne CM,Banka P,Mendez G,et al.Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616[J].J Am Coll Cardiol,2023,81(16):1553-1564.DOI:10.1016/j.jacc.2023.02.018.
• [45]Horie T,Ono K.VERVE-101:a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients[J].Eur Heart J Cardiovasc Pharmacother,2023,pvad103.DOI:10.1093/ehjcvp/pvad103.
• [46]Lee RG,Mazzola AM,Braun MC,et al.Efficacy and safety of an investigational single-course CRISPR baseediting therapy targeting PCSK9 in nonhuman primate and mouse models[J].Circulation,2023,147(3):242-253.DOI:10.1161/CIRCULATIONAHA.122.062132.